Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry
Language English Country Ireland Media print
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
30270071
DOI
10.1016/j.atherosclerosis.2018.08.008
PII: S0021-9150(18)31257-7
Knihovny.cz E-resources
- Keywords
- Ezetimibe, Familial hypercholesterolemia, LDL-C goal attainment, LDL-Cholesterol, Statins, Treatment pattern,
- MeSH
- Anticholesteremic Agents adverse effects therapeutic use MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Down-Regulation MeSH
- Ezetimibe therapeutic use MeSH
- Phenotype MeSH
- Genetic Predisposition to Disease MeSH
- Genetic Markers MeSH
- Heterozygote MeSH
- Risk Assessment MeSH
- Hyperlipoproteinemia Type II blood drug therapy epidemiology genetics MeSH
- Serine Proteinase Inhibitors therapeutic use MeSH
- Cardiovascular Diseases epidemiology prevention & control MeSH
- Drug Therapy, Combination MeSH
- Cholesterol, LDL blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- PCSK9 Inhibitors MeSH
- Proprotein Convertase 9 metabolism MeSH
- Cross-Sectional Studies MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Slovakia epidemiology MeSH
- Names of Substances
- Anticholesteremic Agents MeSH
- Biomarkers MeSH
- Ezetimibe MeSH
- Genetic Markers MeSH
- Serine Proteinase Inhibitors MeSH
- Cholesterol, LDL MeSH
- PCSK9 Inhibitors MeSH
- PCSK9 protein, human MeSH Browser
- Proprotein Convertase 9 MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
BACKGROUND AND AIMS: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. METHODS: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. RESULTS: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p=0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. CONCLUSIONS: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.
References provided by Crossref.org
